Prognostic role of CD133 expression in colorectal cancer: a meta-analysis
- PMID: 23216926
- PMCID: PMC3532409
- DOI: 10.1186/1471-2407-12-573
Prognostic role of CD133 expression in colorectal cancer: a meta-analysis
Abstract
Background: CD133 has been identified as a putative cancer stem cell marker in colorectal cancer (CRC). However, the clinical and prognostic significance of CD133 in CRC remains controversial.
Methods: Publications were identified which assessed the clinical or prognostic significance of CD133 in CRC up to October 2012. A meta-analysis was performed to clarify the association between CD133 expression and clinical outcomes.
Results: A total of 12 studies met the inclusion criteria, and comprised 3652 cases. Analysis of these data showed that CD133 was not significantly associated with the depth of CRC invasion (odds ratio [OR] = 1.44, 95% confidence interval [CI]: 0.77-2.68, Z = 1.15, P = 0.252) or tumor differentiation (OR = 0.63, 95% CI: 0.28-1.46, Z = -1.06, P = 0.286). Also, there was no statistically significant association of CD133 with lymph node metastasis (OR = 1.16, 95% CI: 0.87-1.54, Z = 1.05, P = 0.315) or lymphatic invasion (OR = 1.08, 95% CI: 0.81-1.43, Z = 0.53, P = 0.594). However, in identified studies, overexpression of CD133 was highly correlated with reduced overall survival (relative risk [RR] = 2.14, 95% CI: 1.45-3.17, Z = 3.81, P = 0.0001).
Conclusions: CD133 may play an important role in the progression of CRC, and overexpression of CD133 is closely related with poorer patient survival. If these findings are confirmed by well-designed prospective studies, CD133 may be a useful maker for clinical applications.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3532409/bin/1471-2407-12-573-1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3532409/bin/1471-2407-12-573-2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3532409/bin/1471-2407-12-573-3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3532409/bin/1471-2407-12-573-4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3532409/bin/1471-2407-12-573-5.gif)
Similar articles
-
CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis.PLoS One. 2013;8(2):e56380. doi: 10.1371/journal.pone.0056380. Epub 2013 Feb 11. PLoS One. 2013. PMID: 23409180 Free PMC article. Review.
-
Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.Scand J Gastroenterol. 2012 Oct;47(10):1211-7. doi: 10.3109/00365521.2012.694904. Epub 2012 Aug 3. Scand J Gastroenterol. 2012. PMID: 22856425
-
Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer.Cancer Genomics Proteomics. 2014 Sep-Oct;11(5):259-66. Cancer Genomics Proteomics. 2014. PMID: 25331798
-
Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients.Oncol Rep. 2010 Nov;24(5):1201-12. doi: 10.3892/or_00000973. Oncol Rep. 2010. PMID: 20878111
-
CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients: An updated meta-analysis of 37 studies.Medicine (Baltimore). 2018 Jun;97(23):e10446. doi: 10.1097/MD.0000000000010446. Medicine (Baltimore). 2018. PMID: 29879012 Free PMC article. Review.
Cited by
-
Colorectal Cancer Stem Cell Biomarkers: Biological Traits and Prognostic Insights.Curr Pharm Des. 2024;30(18):1386-1397. doi: 10.2174/0113816128291321240329050945. Curr Pharm Des. 2024. PMID: 38623972 Review.
-
Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons.Int J Mol Sci. 2023 Dec 12;24(24):17398. doi: 10.3390/ijms242417398. Int J Mol Sci. 2023. PMID: 38139228 Free PMC article. Review.
-
Expression and Prognostic Significance of Stem Cell Marker CD133 in Survival Rate of Patients with Colon Cancer.Oncol Ther. 2022 Dec;10(2):451-461. doi: 10.1007/s40487-022-00205-4. Epub 2022 Aug 18. Oncol Ther. 2022. PMID: 35980560 Free PMC article.
-
Cancer stem cell marker expression and methylation status in patients with colorectal cancer.Oncol Lett. 2022 May 27;24(1):231. doi: 10.3892/ol.2022.13352. eCollection 2022 Jul. Oncol Lett. 2022. PMID: 35720495 Free PMC article.
-
Serum amyloid A protein in cancer prognosis: a meta-analysis and systematic review.Transl Cancer Res. 2021 May;10(5):2255-2264. doi: 10.21037/tcr-20-3417. Transl Cancer Res. 2021. PMID: 35116543 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous